Ser345
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Ser345 - PR (human)

Site Information
AFAPPRSsPCASSTP    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: PR (rat): S344, PR iso2 (human): S181, PR (mouse): S343, PR (chicken): S259
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: [32P] bio-synthetic labeling (6, 8), electrophoretic mobility shift (8), immunoprecipitation (1), mass spectrometry (5), mutation of modification site (3, 4), peptide sequencing (8), phospho-antibody (1, 2, 4), phosphopeptide mapping (6, 8), western blotting (1, 2)
Disease tissue studied: breast cancer (1, 2, 4, 6, 8)
Relevant cell line - cell type - tissue: COS (fibroblast) (1, 3), HeLa (cervical) (1, 2), SF9 (5, 6), T47D (breast cell) (1, 2, 4, 6, 8)

Controlled by
Treatments: AG1478 (4), asoprisnil (2), EGF (4), lonaprisan (2), onapristone (2), PP2 (4), progestin R5020 (1, 2, 4, 5, 8), RU-486 (2), SB203580 (4), U0126 (4)

Downstream Regulation
Effects of modification on PR: molecular association, regulation (4)
Effects of modification on biological processes: transcription, induced (4, 7)
Induce interaction with: SP1 (human) (4)


References

1

Hagan CR, Knutson TP, Lange CA (2013) A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res 41, 8926-42
23921636   Curated Info

2

Busia L, Faus H, Hoffmann J, Haendler B (2011) The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. Mol Cell Endocrinol 333, 37-46
21138753   Curated Info

3

Wardell SE, Narayanan R, Weigel NL, Edwards DP (2010) Partial Agonist Activity of the Progesterone Receptor Antagonist RU486 Mediated by an Amino-Terminal Domain Coactivator and Phosphorylation of Serine400. Mol Endocrinol 24, 335-45
20008003   Curated Info

4

Faivre EJ, Daniel AR, Hillard CJ, Lange CA (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22, 823-37
18202149   Curated Info

5

Knotts TA, et al. (2001) Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem 276, 8475-83
11110801   Curated Info

6

Beck CA, et al. (1996) Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. J Biol Chem 271, 19546-55
8702648   Curated Info

7

Takimoto GS, et al. (1996) Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J Biol Chem 271, 13308-16
8662865   Curated Info

8

Zhang Y, et al. (1995) Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol 9, 1029-40
7476977   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.